Group 1 - Xinda Biologics reported a total product revenue exceeding 5.2 billion yuan in the first half of 2025, achieving a strong growth of over 35% year-on-year, driven by both oncology and comprehensive pipeline [1] - Eli Lilly's orforglipron demonstrated significant weight loss results in the ATTAIN-1 clinical trial, with the highest dose group (36 mg) achieving an average weight reduction of 12.4 kg, enhancing market confidence in the company's weight loss portfolio [1] Group 2 - AstraZeneca's Fasenra received approval for a new indication in China for the maintenance treatment of severe eosinophilic asthma in children aged 6 to <12 years, further solidifying its market position in respiratory diseases [2] Group 3 - Gan & Lee Pharmaceuticals reported a 57.18% increase in revenue to 2.067 billion yuan and a 101.96% increase in net profit to 604 million yuan in the first half of 2025, indicating strong business growth and enhanced profitability [3] Group 4 - Buchang Pharma announced an exclusive supply agreement with GOODFELLOW in the Philippines for the new biological drug Efparepoetin alfa, marking a significant step in the company's internationalization strategy and enhancing its brand value [4]

Core Insights - AstraZeneca (AZN.US) announced the approval of its first respiratory biologic, Fasenra (benralizumab), for a new indication in China, specifically for the maintenance treatment of severe eosinophilic asthma (SEA) in children aged 6 to under 12 years [1] Group 1: Approval and Clinical Trials - The approval is based on positive results from the global multicenter, open-label TATE Phase III clinical trial [1] - This trial was conducted in the United States and Japan to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and long-term safety of benralizumab in SEA pediatric patients aged 6-11 years [1] Group 2: Sales Performance - Since its initial approval, benralizumab has shown steady sales growth, entering the $1 billion sales club in 2021 [1] - Global sales are projected to reach $1.689 billion in 2024, reflecting an 8.76% year-over-year growth [1] - According to the semi-annual report disclosed for 2025, the drug's sales for the first half of the year reached $920 million, marking an 18% year-over-year increase [1]

Core Viewpoint - AstraZeneca has received approval for its respiratory biologic Fasenra (benralizumab injection) for a new indication in China, specifically for the maintenance treatment of severe eosinophilic asthma (SEA) in children aged 6 to under 12 years [1] Group 1: Approval and Clinical Trials - The approval is based on positive results from the global multicenter, open-label TATE Phase III clinical trial [1] - This trial was conducted in the United States and Japan to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and long-term safety of benralizumab in SEA pediatric patients aged 6-11 years [1] Group 2: Sales Performance - Since its initial approval, benralizumab has shown steady sales growth, entering the $1 billion sales club in 2021 [1] - Global sales are projected to reach $1.689 billion in 2024, reflecting an 8.76% year-over-year growth [1] - According to the semi-annual report disclosed for 2025, the drug's sales for the first half of the year reached $920 million, representing an 18% year-over-year increase [1]

Core Viewpoint - AstraZeneca (AZN.US) has received approval for its first respiratory biologic, Fasenra® (benralizumab injection), for a new indication in China, specifically for the maintenance treatment of severe eosinophilic asthma (SEA) in children aged 6 to under 12 years [1] Group 1: Approval and Clinical Trials - The approval is based on positive results from the global multicenter, open-label TATE Phase III clinical trial [1] - This trial was conducted in the United States and Japan to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and long-term safety of benralizumab in SEA pediatric patients aged 6-11 years [1] Group 2: Sales Performance - Since its initial approval, benralizumab has shown steady sales growth, entering the $1 billion sales club in 2021 [1] - Global sales are projected to reach $1.689 billion in 2024, reflecting an 8.76% year-on-year growth [1] - According to the semi-annual report disclosed for 2025, the drug's sales for the first half of the year reached $920 million, representing an 18% year-on-year increase [1]